Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$42.92−0.81 (-1.85%)
Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –
Rigel Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rigel Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $87.05M, down 16.8% year over year. For fiscal 2025 it was $125.47M, up 418.6% from the year before. The highest annual figure on record is $125.47M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.47M | +418.6% |
| FY2024 | Dec 31, 2024 | $24.19M | – |
| FY2023 | Dec 31, 2023 | -$20.49M | – |
| FY2022 | Dec 31, 2022 | -$55.55M | – |
| FY2021 | Dec 31, 2021 | -$12.50M | – |
| FY2020 | Dec 31, 2020 | -$28.97M | – |
| FY2019 | Dec 31, 2019 | -$69.09M | – |
| FY2018 | Dec 31, 2018 | -$72.68M | – |
| FY2017 | Dec 31, 2017 | -$79.62M | – |
| FY2016 | Dec 31, 2016 | -$69.74M | – |
| FY2015 | Dec 31, 2015 | -$51.74M | – |
| FY2014 | Dec 31, 2014 | -$91.25M | – |
| FY2013 | Dec 31, 2013 | -$89.47M | – |
| FY2012 | Dec 31, 2012 | -$99.38M | – |
| FY2011 | Dec 31, 2011 | -$86.37M | -344.6% |
| FY2010 | Dec 31, 2010 | $35.32M | – |
| FY2009 | Dec 31, 2009 | -$112.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $23.58M | -61.4% |
| Q1 FY2026 | Mar 31, 2026 | $11.89M | -7.0% |
| Q4 FY2025 | Dec 31, 2025 | $23.17M | +39.1% |
| Q3 FY2025 | Sep 30, 2025 | $28.42M | +102.2% |
| Q2 FY2025 | Jun 30, 2025 | $61.10M | +13569.6% |
| Q1 FY2025 | Mar 31, 2025 | $12.77M | – |
| Q4 FY2024 | Dec 31, 2024 | $16.66M | +747.2% |
| Q3 FY2024 | Sep 30, 2024 | $14.06M | – |
| Q2 FY2024 | Jun 30, 2024 | $447.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.97M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.97M | -5.4% |
| Q3 FY2023 | Sep 30, 2023 | -$4.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.73M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.26M | -162.9% |
| Q4 FY2021 | Dec 31, 2021 | -$21.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.05M | – |
| Q1 FY2021 | Mar 31, 2021 | $41.76M | +98.6% |
| Q4 FY2020 | Dec 31, 2020 | -$18.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.78M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.39M | – |
| Q1 FY2020 | Mar 31, 2020 | $21.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.34M | -784.7% |
| Q3 FY2019 | Sep 30, 2019 | -$12.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.38M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.53M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.37M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.73M | – |
| Q4 FY2017 | Dec 31, 2017 | -$26.22M | – |
| Q3 FY2017 | Sep 30, 2017 | -$17.86M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.20M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.79M | – |
| Q3 FY2016 | Sep 30, 2016 | -$22.74M | – |
See a number that looks wrong?